Stock Track | Haemonetics Soars 8.22% in Pre-market on Strong Q4 Earnings Beat and Upbeat Fiscal 2027 Guidance

Stock Track
May 07

Haemonetics Corporation's stock surged 8.22% in pre-market trading on Thursday, following the release of its fourth-quarter fiscal 2026 financial results that exceeded analyst expectations.

The medical technology company reported adjusted earnings per share of $1.29 for the quarter, surpassing the FactSet consensus estimate of $1.27. Quarterly net revenue reached $346.4 million, also beating the expected $336.8 million and representing growth from the $330.6 million reported a year earlier.

Additionally, Haemonetics provided a positive outlook for fiscal 2027, guiding for reported revenue growth in the range of 4% to 7%. The company stated that adjusted diluted earnings per share for the fiscal year are expected to be comparable to this revenue growth rate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10